USFDA inspection at Bengaluru facility ends with one observation

Regulatory & Legal View source PDF Explain this filing

ONESOURCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.0%Reaction day

₹1659.40

prior close

₹1685.40

announcement price

In-mkt

timing

Nifty Smallcap 250market+1.0%-0.0% vs market

Pharmaceuticals peers, median of 164sector+0.0%+1.0% vs sector

On the reaction day the stock moved in line with Nifty Smallcap 250 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.2

15m

+0.5

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.0+1.0-0.0+0.0+1.0

Next day

+0.6+1.1-0.5+0.4+0.2

+0.2+1.6-1.4+0.0+0.2

-1.6+0.9-2.5-0.3-1.3

-2.9-1.1-1.7-1.2-1.7

-2.1+0.4-2.5-0.7-1.4

+0.8+2.1-1.3+0.4+0.4

15d

-1.2-0.8-0.3-1.5+0.4

-6.3+2.1-8.3-0.3-6.0

-7.0+2.6-9.6+1.1-8.1

-10.3-0.8-9.4+0.5-10.7

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA conducted a routine cGMP inspection at OneSource Specialty Pharma's Sterile Product Division facility in Bengaluru from June 22 to June 30, 2026. The inspection concluded with one observation. The company will respond comprehensively to the FDA within the stipulated timeframe and will update stock exchanges on further developments.

Likely market impact

Single observation is generally manageable; outcome of company response and any FDA classification will determine impact on US business.